Ultra Clean Holdings, Inc.
UCTT
$121.28
+8.66%
Ultra Clean Holdings, Inc. is a key supplier to the semiconductor capital equipment industry, manufacturing and supplying critical production tools, modules, and subsystems such as precision robotic solutions, gas delivery systems, and wafer cleaning subsystems. The company operates as a critical niche player in the semiconductor supply chain, providing essential components that enable the fabrication of advanced chips. The current investor narrative is intensely focused on the stock's explosive price performance, which appears to be driven by a dramatic recovery and re-rating within the cyclical semiconductor equipment sector, potentially fueled by expectations of a new capital expenditure upcycle and strong end-market demand. Recent financial trends show a challenging revenue environment, but the stock's massive rally suggests the market is heavily discounting a future inflection point in fundamentals.…
UCTT
Ultra Clean Holdings, Inc.
$121.28
Investment Opinion: Should I buy UCTT Today?
Rating: Hold. The core thesis is that UCTT represents a high-risk, high-reward bet on a semiconductor equipment cycle recovery, but the explosive 412% rally has likely pulled forward most of the near-term upside, creating an unfavorable risk/reward balance at current levels. The analyst consensus is bullish, but coverage is too thin to be conclusive.
The supporting evidence is mixed. On one hand, the valuation appears compelling with a trailing PS of 0.57, a 76% discount to its own history, and a forward PE of 27.7x based on a projected $7.99 EPS. Positive free cash flow ($14.7M TTM) and strong liquidity (current ratio 3.19) are financial strengths. On the other hand, fundamentals are weak with a -10.05% YoY revenue decline, a net loss in Q4, and a negative ROE of -25.49%. The stock's technical position is overextended, trading near its 52-week high after a parabolic move.
Key risks that could invalidate this Hold thesis are: 1) A delay in the semiconductor capex recovery, leading to further revenue contraction; 2) An inability to achieve the projected $7.99 EPS, causing a valuation de-rating. This rating would upgrade to a Buy if the stock experiences a meaningful pullback (e.g., to the $70-$80 range) offering a better entry point, or if Q1 2026 earnings show clear evidence of the anticipated revenue and margin inflection. It would downgrade to a Sell if revenue growth fails to turn positive in the next two quarters or if gross margins fall below 14%. Relative to its own history, the stock is undervalued on a sales basis, but relative to its near-term fundamentals and profit profile, it appears fully valued or slightly overvalued, pricing in a perfect recovery.
Sign up to view all
UCTT 12-Month Price Forecast
UCTT is a binary, momentum-driven trade on a semiconductor cycle turn, not a fundamental growth story at this point. The AI assessment is neutral due to the extreme tension between compelling valuation on paper and alarming fundamental deterioration in reality. The stock's fate hinges entirely on the timing and magnitude of the industry recovery. Confidence is medium because the limited data (single analyst) increases uncertainty. The stance would upgrade to bullish on a significant price pullback that improves the risk/reward profile, coupled with concrete quarterly evidence of revenue growth reacceleration. It would turn bearish if the next earnings report shows further sequential revenue decline or margin compression, signaling the recovery thesis is flawed.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ultra Clean Holdings, Inc.'s 12-month outlook, with a consensus price target around $157.66 and implied upside of +30.0% versus the current price.
Average Target
$157.66
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$97 - $158
Analyst target range
Analyst coverage appears limited, with data indicating only one analyst providing estimates, which suggests this is a smaller-cap name with less institutional research focus. This limited coverage can lead to higher volatility and less efficient price discovery. The sole analyst provides an average EPS estimate of $7.99 for the coming period, which, against a negative trailing EPS, implies a dramatic swing to profitability is anticipated. The average revenue estimate is $4.55 billion, representing a substantial projected increase from recent quarterly run rates. The institutional ratings data shows a consistent bullish stance from the few firms that do cover it, with Needham and Oppenheimer maintaining 'Buy' or 'Outperform' ratings through 2025 and into early 2026 without any downgrades, indicating steady institutional support for the long-term thesis despite near-term fundamental challenges.
Bulls vs Bears: UCTT Investment Factors
The investment debate for UCTT is a classic clash between powerful momentum and deteriorating fundamentals. The bull case, currently supported by stronger market evidence given the 412% rally, is predicated on a deep-value re-rating and the market's forward-looking anticipation of a sharp cyclical recovery in semiconductor equipment spending, as hinted by analyst projections. The bear case highlights the stark reality of declining revenues, net losses, and the extreme technical overextension of the stock. The single most important tension is whether the company can deliver on the analyst-implied dramatic earnings recovery (to $7.99 EPS) fast enough to justify its recent parabolic price move, or if the current valuation is a speculative bubble that will deflate when faced with slower-than-expected fundamental improvement.
Bullish
- Massive Price Momentum & Sector Re-rating: The stock has surged 412.47% over the past year and 98.11% over the past three months, dramatically outperforming the S&P 500. This explosive move suggests the market is heavily discounting a fundamental inflection point, driven by a re-rating within the cyclical semiconductor equipment sector and expectations of a new capital expenditure upcycle.
- Extremely Low Valuation on Sales Basis: UCTT trades at a trailing Price-to-Sales (PS) ratio of 0.57, a 76% discount to its own historical PS ratio of 2.33 from Q4 2025. This deep discount to its revenue base, coupled with a forward PS of approximately 0.26 based on analyst revenue estimates, suggests significant embedded value if the anticipated revenue growth materializes.
- Strong Analyst Growth Expectations: The sole analyst covering the stock projects a dramatic swing to profitability with an average EPS estimate of $7.99 and forecasts revenue to reach $4.55 billion. This implies a substantial recovery from the current quarterly run rate of ~$506 million, providing a clear fundamental catalyst for the recent price action.
- Robust Liquidity & Positive Free Cash Flow: The company maintains a strong current ratio of 3.19, indicating ample short-term liquidity. Furthermore, it generated positive free cash flow of $14.7 million over the trailing twelve months, providing internal funding flexibility to navigate the current downcycle without excessive reliance on external capital.
Bearish
- Severe Fundamental Deterioration & Losses: Q4 2025 revenue declined 10.05% YoY to $506.7 million, and the company reported a net loss of $3.3 million. The trailing twelve-month net margin is -8.82% and ROE is -25.49%, indicating significant shareholder value destruction and raising questions about the sustainability of the valuation re-rating absent a sharp earnings recovery.
- Parabolic Rally Creates High Correction Risk: Trading just 1.2% below its 52-week high of $110.25 after a 412% surge, the stock is technically overextended. With a beta of 1.95, it is nearly twice as volatile as the market, making it highly vulnerable to a sharp pullback, especially if the anticipated growth inflection is delayed or disappoints.
- Gross Margin Pressure & Profitability Challenges: Gross margin in Q4 2025 was 15.26%, down from 16.20% in the year-ago quarter. This margin pressure, combined with a negative net margin, highlights operational challenges. The company's core profitability is thin, with an operating margin of just 2.13% in the latest quarter.
- Limited Analyst Coverage & High Uncertainty: Only one analyst provides estimates for UCTT, leading to less efficient price discovery and higher volatility. The investment thesis is heavily reliant on this single analyst's forecast for a dramatic EPS recovery to $7.99, which carries significant execution risk.
UCTT Technical Analysis
The stock is in a powerful, sustained uptrend, having appreciated by a staggering 412.47% over the past year. As of the latest close at $108.90, it is trading near the top of its 52-week range, just 1.2% below its 52-week high of $110.25, indicating strong momentum but also potential overextension and vulnerability to a pullback. The short-term momentum is exceptionally strong, with the stock up 28.07% over the past month and 98.11% over the past three months, significantly outpacing the S&P 500's returns of -0.08% and 12.0% over the same periods, respectively, which highlights its explosive relative strength and high-beta nature. Key technical support is at the 52-week low of $19.51, but given the magnitude of the rally, more relevant near-term support likely resides around the $80-$85 level from recent consolidation. A beta of 1.95 confirms the stock is nearly twice as volatile as the broader market, which necessitates careful risk management, especially after such a parabolic move where a breakdown from recent highs could trigger a sharp correction.
Beta
1.95
1.95x market volatility
Max Drawdown
-29.7%
Largest decline past year
52-Week Range
$20-$123
Price range past year
Annual Return
+495.4%
Cumulative gain past year
| Period | UCTT Return | S&P 500 |
|---|---|---|
| 1m | +57.5% | +1.8% |
| 3m | +110.3% | +15.1% |
| 6m | +373.8% | +9.7% |
| 1y | +495.4% | +25.0% |
| ytd | +343.9% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UCTT Fundamental Analysis
The company's revenue trajectory shows contraction, with Q4 2025 revenue of $506.7 million representing a 10.05% year-over-year decline, continuing a trend from the prior quarter's $510 million. The Product segment, at $442.4 million, remains the dominant revenue driver, but overall top-line weakness persists. Profitability is under pressure, as evidenced by a net loss of $3.3 million in Q4 2025, a gross margin of 15.26%, and a trailing twelve-month net margin of -8.82%. However, the operating margin was a positive 2.13% in the latest quarter, indicating the core business is marginally profitable before interest and taxes, but significant bottom-line losses have been driven by other expenses, as seen in Q2 2025's large $162 million net loss. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.14, but strong liquidity is a positive with a current ratio of 3.19. Free cash flow over the trailing twelve months is positive at $14.7 million, providing some internal funding flexibility, though the negative return on equity of -25.49% signals significant shareholder value destruction based on recent earnings.
Quarterly Revenue
$506700000.0B
2025-12
Revenue YoY Growth
-0.10%
YoY Comparison
Gross Margin
+0.15%
Latest Quarter
Free Cash Flow
$14700000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UCTT Overvalued?
Given the company reported negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.57, which is extremely low and suggests the market is valuing the company at a deep discount to its revenue base. For context, the forward-looking valuation implied by analyst estimates for revenue ($4.55 billion) and the current market cap yields a forward PS ratio of approximately 0.26, indicating expectations for significant revenue growth. The stock trades at a substantial discount to its own historical valuation, as its PS ratio of 0.57 is far below the 2.33 level seen at the end of Q4 2025, representing a 76% compression. This historical de-rating, despite the soaring stock price, is due to revenue growth not keeping pace with the market cap explosion, placing the stock at the very low end of its own historical valuation band, which could signal either a deep value opportunity or that the market expects a fundamental deterioration in the sales multiple. The extremely low PEG ratio of 0.0076, while often signaling undervaluation relative to growth, is likely distorted by negative or highly volatile earnings.
PE
-6.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -196x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-53.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's weak profitability profile and its dependence on a swift cyclical recovery. The trailing net margin of -8.82% and a negative ROE of -25.49% indicate the business is currently destroying shareholder value. Gross margins have compressed to 15.26%, and while free cash flow is positive at $14.7 million TTM, it is modest relative to the market cap. The debt-to-equity ratio of 1.14 indicates moderate leverage, but servicing this debt could become challenging if the operating margin, currently a thin 2.13%, deteriorates further. The investment thesis is entirely contingent on revenue reversing its -10.05% YoY decline and expanding towards the analyst target of $4.55 billion.
Market & Competitive Risks are elevated due to UCTT's high-beta (1.95) nature and its position in the cyclical semiconductor equipment supply chain. The stock's massive rally has created extreme valuation dislocation; its PS ratio of 0.57 is a 76% discount to its own recent history, but this also means any disappointment could trigger a violent reversion. The limited analyst coverage (only one firm) exacerbates volatility and information asymmetry. The primary risk is a sector-wide delay in the anticipated capital expenditure upcycle, which would prolong revenue contraction and invalidate the growth assumptions baked into the current price. Competitive pressures could further squeeze already-low margins.
Worst-Case Scenario involves a failure of the semiconductor equipment recovery to materialize in 2026, leading to consecutive quarters of revenue misses and sustained net losses. This would trigger analyst downgrades, a loss of institutional confidence, and a rapid unwinding of the speculative momentum trade. Given the stock's 412% run-up and high beta, a sharp correction to a level that reflects the ongoing fundamental challenges is plausible. A realistic downside could see the stock retracing to the $50-$60 range, representing a decline of 45-55% from the current price of $108.90, as it seeks a valuation support level aligned with a more pessimistic growth outlook, well above the 52-week low of $19.51 which reflects a different capital structure and market sentiment era.
FAQ
The key risks are: 1) Execution/Cyclical Risk: The entire thesis depends on a swift semiconductor capex recovery. If delayed, revenue could continue to contract (-10.05% YoY in Q4), and losses could persist. 2) Valuation/Momentum Risk: After a 412% surge, the stock is prone to a sharp correction (max drawdown potential of -30%+), especially with its high beta of 1.95. 3) Profitability Risk: Gross margins are thin at 15.26% and ROE is deeply negative at -25.49%, indicating poor capital allocation and operational challenges. 4) Information Risk: With only one analyst providing estimates, there is less scrutiny and higher uncertainty around growth projections, increasing volatility.
The 12-month forecast is highly bifurcated, with three distinct scenarios. The Base Case (50% probability) sees the stock trading between $95 and $115 as a moderate industry recovery unfolds, aligning with the current analyst revenue target of $4.55B. The Bull Case (25% probability) projects a surge to $130-$150 if a strong upcycle drives earnings above estimates and triggers a valuation re-rating. The Bear Case (25% probability) warns of a correction to $50-$70 if the recovery is delayed, fundamentals worsen, and momentum reverses. The Base Case is most likely, implying the stock may struggle for significant near-term gains from current levels after its massive run.
UCTT presents a valuation paradox. On a Price-to-Sales (PS) basis, it appears deeply undervalued, trading at a trailing PS of 0.57, which is a 76% discount to its own historical multiple of 2.33. This suggests the market is pricing in significant fundamental deterioration or skepticism about future growth. However, given the company's recent net losses (-8.82% net margin) and declining revenue, the low multiple may be warranted. The forward PE of 27.7x, based on a projected $7.99 EPS, is reasonable for a growth recovery story. Overall, the stock is fairly valued to slightly overvalued relative to its current weak fundamentals, but could be undervalued if the analyst's aggressive growth projections are met.
UCTT is a high-risk, high-potential-reward stock that is not a good buy for most investors at its current price near $109. After a 412% rally in one year, the stock is technically overextended and prices in a near-perfect cyclical recovery. For aggressive investors who can tolerate extreme volatility (beta of 1.95) and are confident in a strong 2026 semiconductor equipment upcycle, waiting for a significant pullback to the $70-$85 range would improve the risk/reward profile. The analyst target implies substantial upside, but it is based on a single forecast, making execution highly uncertain.
UCTT is unsuitable for short-term trading due to its extreme volatility (beta 1.95) and the speculative nature of its current price move. It pays no dividend, offering no income. For investors with a long-term horizon (3-5 years), it could be a speculative holding within a diversified portfolio, betting on a full semiconductor cycle recovery. However, given its cyclicality and current weak fundamentals, it is best categorized as a tactical, rather than strategic, long-term hold. The minimum suggested holding period is 12-18 months to fully assess whether the anticipated recovery is materializing, but investors must be prepared for significant price swings during that time.